ELISpot・FluoroSpotアッセイの世界市場：市場規模・シェア分析 (製品種類別・用途別・エンドユーザー別)、産業需要の予測 (～2030年)

世界のELISpot・FluoroSpotアッセイの市場規模は、2023年に2億8,950万米ドルで、2024年から2030年にかけてCAGR7.9%で拡大し、2030年には4億9,080万米ドルに達すると思われます。

アッセイキットが最大のシェアを占める

感染症や慢性疾患の罹患率の増加、それに伴うアッセイキットの開発により、アッセイキットはこの10年末までに市場をリードすることになると思われます。

ELISpotアッセイは、インターフェロン、炎症性メディエーター、インターロイキンなどの免疫メディエーターに対するワクチン効率を調べるために使用されます。また、このアッセイの主な利点は、費用対効果が高く、結果が迅速に表示されることです。

病院と診療所が主要エンドユーザー

2023年の市場シェアは、病院と診療所が60%で最大でした。これは、特に新興国において、病院や診療所が疾患診断のために多くの患者に好まれているためです。

北米が市場のリーダー

北米は、2023年には55%のシェアを獲得し、地域別で最大の市場となっています。米国国勢調査局によると、米国には65歳以上の成人が約5,600万人おり、同国の総人口の約16.9%を占めています。

中国がアジア太平洋市場をリードする

アジア太平洋地域では、中国が最も急速に成長する市場となります。これには、がんやその他の慢性疾患の流行、研究開発活動の重点化、患者数の増加、医療支出の急増が大きく関係しています。

当レポートでは、世界のELISpot・FluoroSpotアッセイの市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、製品種類別・用途別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品種類別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品種類別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ (MEA) 市場

第12章 米国市場

• 概要
• 市場収益：製品種類別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Oxford Immunotec
• Cellular Technology Limited
• Mabtech AB
• Becton, Dickinson and Company
• Bio-Techne Corporation

第31章 付録

The value of the ELISpot and FluoroSpot assay market was USD 289.5 million in 2023, and it will power at a compound annual growth rate of 7.9% during 2024-2030, to touch USD 490.8 million by 2030.

Market Drivers

Some driving factors of the industry are the growing occurrence of infectious and chronic diseases at a global level, particularly HIV, and the growing elderly population.

ELISpot and FluoroSpot are performed for several diseases, for instance, cancer, infectious diseases, and, autoimmune ailments. The ELISpot assay clearly spots the number of cytokine-secreting cell with high specialty and sensitivity.

These benefits make it an effective tool for measuring the degree of adaptive and innate immune responses.

As stated by the CDC's NCEZID, the infectious disease risk is increasing incessantly due to the change in climate all over the world.

Lyme disease, Valley fever, and West Nile disease are some infectious diseases, rising in prevalence and spreading to novel regions of the U.S. This is because of the warmer summers, milder winters, and fewer days with frost.

Assay Kits Hold Largest Share

Assay kits will lead the market by the end of this decade because of the growing incidence of infectious and chronic ailments, accompanied by the development in assay kits.

The ELISpot assay is used to examine the vaccine efficiency on immune mediators, for example, interferons, pro-inflammatory mediators, and interleukins. Additionally, the main benefit of this assay is that it is cost-effective and displays results quickly.

Hospitals and Clinics are the Major End Users

Hospitals and clinics were the leaders of the market, with a share of 60%, in 2023. This is because hospitals and clinics and preferred by most patients for disease diagnosis, particularly in emerging countries.

Furthermore, with continued efforts of the government, the count of such medical centers is on the rise, at a global level, which drives the demand for all sorts of therapeutic and diagnostic equipment at these places.

For addressing the huge demand for biopharmaceuticals, there is a growing emphasis on research and, related spending. The capability of biopharmaceuticals for treating ailments that were incurable before has brought about the release of these kinds of new medications in the market.

Therefore, the market under investigation will grow by the end of this decade.

North America is the Leader of the Market

North America was the regional leader of the market, with a 55% share, in 2023. As per the U.S. Census Bureau, approximately 56 million adults aged 65 or more are in the U.S. and make about 16.9% of the total population of the country.

Further, there will be over 73 million older adults by the time 2030 comes to an end, which means over 20% of people will be older. The total count of adults aged 65 and more will increase to 85.7 million by 2050 and will comprise 22% of the total population of the nation.

China Leads the Pack in the APAC Market

In the APAC region, China will be the fastest-growing market. This has a lot to do with the prevalence of cancer and other chronic ailments, increasing emphasis on research and development activities, rising patient populace, and surging healthcare spending.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product Type (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by End User (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product Type (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by End User (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product Type (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product Type (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product Type (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product Type (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product Type (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product Type (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product Type (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product Type (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product Type (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product Type (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product Type (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product Type (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product Type (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product Type (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product Type (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product Type (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product Type (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product Type (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product Type (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product Type (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product Type (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Oxford Immunotec
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Cellular Technology Limited
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Mabtech AB
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Becton, Dickinson and Company
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Bio-Techne Corporation
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports